Merck & Company (MRK) 56.47 $MRK
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Business Wire - Thu Apr 17, 5:22PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
FDA OKs Merck tablet to reduce ragweed allergies
By The Associated Press - AP - Thu Apr 17, 4:11PM CDT
WHITEHOUSE STATION, N.J. (AP) — U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
GlobeNewswire - Thu Apr 17, 2:13PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for RAGWITEK.
Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Merck Serono's President & CEO Belen Garijo has Been Appointed to Board of Directors of L'Oreal
PR Newswire Europe - Thu Apr 17, 11:39AM CDT
DARMSTADT, Germany and PARIS, April 17, 2014 /PRNewswire/ --
Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal
PR Newswire - Thu Apr 17, 11:37AM CDT
Merck Serono, the biopharmaceutical division of Merck, announced today that Belén Garijo, President & Chief Executive Officer of Merck Serono, has been appointed as an independent Director of L'Oréal for a period of four years. The appointment of Belén Garijo as a new member of the Board of Directors of L'Oréal was approved by shareholders at the Company's 2014 Annual General Meeting held today in Paris.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Smartphone apps remind patients to take their meds
By LINDA A. JOHNSON - AP - Wed Apr 16, 11:48AM CDT
Medicine only helps if you take it properly. And adhering to an exact schedule of what to take, and when, can be challenging for patients who are forgetful or need to take several medications.
Global Nasopharyngeal Cancer Clinical Trials Review 2014 - Featuring 19 Companies/Organisations
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/chvvbq/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nasopharyngeal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nasopharyngeal Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Sanofi - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Jiangsu Hengrui Medicine Co., Ltd. - ZonMw - Roche Hong Kong Limited - Lakewood-Amedex Inc. - C. H. Boehringer Sohn AG & Co. KG - Biotech Pharmaceuticals Co., Ltd. - National Cancer Institute - Sun Yat-sen University - Sun Yat-Sen University Cancer Center - Chinese University of Hong Kong - FUDAN University - Baylor College of Medicine - National University Hospital - European Organization for Research and Treatment of Cancer - The University of Hong Kong - University of Washington For more information visit http://www.researchandmarkets.com/research/ch...pharyngeal
Physicians Interactive's Transformative Omnio Medical App Expands from iPad to iPhone, Android Versions
PR Newswire - Wed Apr 16, 6:54AM CDT
Physicians Interactive Inc. (PI), the leading provider of online and mobile clinical resources and solutions for healthcare professionals, today announced it is launching free iPhone and Android versions of its popular Omnio application.
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Business Wire - Thu Apr 17, 5:22PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
FDA OKs Merck tablet to reduce ragweed allergies
By The Associated Press - AP - Thu Apr 17, 4:11PM CDT
WHITEHOUSE STATION, N.J. (AP) — U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
GlobeNewswire - Thu Apr 17, 2:13PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for RAGWITEK. Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Merck Serono's President & CEO Belen Garijo has Been Appointed to Board of Directors of L'Oreal
PR Newswire Europe - Thu Apr 17, 11:39AM CDT
DARMSTADT, Germany and PARIS, April 17, 2014 /PRNewswire/ --
Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal
PR Newswire - Thu Apr 17, 11:37AM CDT
Merck Serono, the biopharmaceutical division of Merck, announced today that Belén Garijo, President & Chief Executive Officer of Merck Serono, has been appointed as an independent Director of L'Oréal for a period of four years. The appointment of Belén Garijo as a new member of the Board of Directors of L'Oréal was approved by shareholders at the Company's 2014 Annual General Meeting held today in Paris.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Smartphone apps remind patients to take their meds
By LINDA A. JOHNSON - AP - Wed Apr 16, 11:48AM CDT
Medicine only helps if you take it properly. And adhering to an exact schedule of what to take, and when, can be challenging for patients who are forgetful or need to take several medications.
Global Nasopharyngeal Cancer Clinical Trials Review 2014 - Featuring 19 Companies/Organisations
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/chvvbq/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nasopharyngeal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nasopharyngeal Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Sanofi - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Jiangsu Hengrui Medicine Co., Ltd. - ZonMw - Roche Hong Kong Limited - Lakewood-Amedex Inc. - C. H. Boehringer Sohn AG & Co. KG - Biotech Pharmaceuticals Co., Ltd. - National Cancer Institute - Sun Yat-sen University - Sun Yat-Sen University Cancer Center - Chinese University of Hong Kong - FUDAN University - Baylor College of Medicine - National University Hospital - European Organization for Research and Treatment of Cancer - The University of Hong Kong - University of Washington For more information visit http://www.researchandmarkets.com/research/ch...pharyngeal
Physicians Interactive's Transformative Omnio Medical App Expands from iPad to iPhone, Android Versions
PR Newswire - Wed Apr 16, 6:54AM CDT
Physicians Interactive Inc. (PI), the leading provider of online and mobile clinical resources and solutions for healthcare professionals, today announced it is launching free iPhone and Android versions of its popular Omnio application.
